Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of Blinatumomab in Combination With Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients With Poor-Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

Next Previous
X
Search
Trial Profile

A Phase 1 Study of Blinatumomab in Combination With Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients With Poor-Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Oct 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Blinatumomab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Acute biphenotypic leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions

    • Most Recent Events

    • 16 Oct 2024 Planned End Date changed from 6 Sep 2024 to 18 Jul 2025.
    • 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition, based on safety and efficacy data, blina + nivo was expanded to include 6 additional pts without additional DLTs. Ongoing analyses of changes in T cell subpopulations, co-signaling molecule expression, and single cell RNA seq results will be presented.
    • 12 Dec 2023 Results reporting efficacy and safety data presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top